Constitutive phosphoinositide 3-kinase/Akt activation represents a favorable prognostic factor in de novo acute myelogenous leukemia patients
- 1 August 2007
- journal article
- clinical trial
- Published by American Society of Hematology in Blood
- Vol. 110 (3) , 1025-1028
Abstract
The phosphoinositide 3-kinase (PI3K/Akt) pathway is activated in acute myelogenous leukemia (AML) and is promising for targeted inhibition. Ninety-two patients with primary AML were analyzed for PI3K/Akt constitutive activation. Fifty percent of the patients presented with constitutive PI3K activation (PI3K +). No difference was observed between PI3K + and PI3K − groups concerning age, sex, white blood cell count, lactate dehydrogenase (LDH) level, bone marrow blast cells, French-American-British (FAB) classification, cytogenetics, RAS or nucleophosmin (NPM) mutations. Slightly more FLT3-ITD was detected in the PI3K − group (P = .048). The complete remission rate was similar between the 2 groups. With a median follow-up of 26 months, we observed for PI3K + and PI3K − patients, respectively, 56% and 33% overall survival (P = .001) and 72% and 41% relapse-free survival (P = .001). Constitutive PI3K/Akt activity is a favorable prognosis factor in AML, even after adjustment for FLT3-ITD, and may confer a particular sensitivity to chemotherapy. A better understanding of the downstream effectors of the PI3K/Akt pathway is needed before targeting in AML.Keywords
This publication has 14 references indexed in Scilit:
- Simultaneous activation of multiple signal transduction pathways confers poor prognosis in acute myelogenous leukemiaBlood, 2006
- Will Kinase Inhibitors Have a Dark Side?New England Journal of Medicine, 2006
- Nucleophosmin status may influence the therapeutic decision in de novo acute myeloid leukemia with normal karyotypeLeukemia, 2006
- A selective inhibitor of the p110δ isoform of PI 3-kinase inhibits AML cell proliferation and survival and increases the cytotoxic effects of VP16Oncogene, 2006
- Constitutive phosphoinositide 3-kinase activation in acute myeloid leukemia is not due to p110δ mutationsLeukemia, 2005
- Essential role for the p110 isoform in phosphoinositide 3-kinase activation and cell proliferation in acute myeloid leukemiaBlood, 2005
- PI3-kinase/Akt is constitutively active in primary acute myeloid leukaemia cells and regulates survival and chemoresistance via NF-kB, MAPkinase and p53 pathwaysLeukemia, 2005
- Survival of acute myeloid leukemia cells requires PI3 kinase activationBlood, 2003
- Constitutive phosphorylation of Akt/PKB protein in acute myeloid leukemia: its significance as a prognostic variableLeukemia, 2003
- High incidence of N and K-Ras activating mutations in multiple myeloma and primary plasma cell leukemia at diagnosisHuman Mutation, 2001